<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01521312</url>
  </required_header>
  <id_info>
    <org_study_id>P101105</org_study_id>
    <nct_id>NCT01521312</nct_id>
  </id_info>
  <brief_title>ACute and Chronic Effects of Saxagliptin</brief_title>
  <acronym>ACCES</acronym>
  <official_title>A Randomized, Double Blind, Placebo Controlled, Pilot Study to Evaluate ACute and Chronic Effects of Saxagliptin on Impaired Glucose Tolerance and micro-and Macro-vascular Integrators</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Glucose ACCES study will explore the acute and long term (12-week treatment) effects of&#xD;
      saxagliptin in patients with impaired glucose tolerance during fasting and after a&#xD;
      standardised breakfast. The investigations will be performed on:&#xD;
&#xD;
        -  glycemic parameters&#xD;
&#xD;
        -  on cardiovascular parameters&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this pilot study is to compare in patients with impaired glucose tolerance the&#xD;
      effects of saxagliptin versus placebo:&#xD;
&#xD;
      (i) on glucose metabolism (ii) on vago-sympathetic activity, arterial stiffness and&#xD;
      endothelial function. A total of 36 patients will be recruited in the department of&#xD;
      Endocrinology-Diabetology-Nutrition of Jean VERDIER hospital, AP-HP, Bondy, France.&#xD;
&#xD;
      The measurements will be performed in the morning 1) at the time of randomisation (Acute&#xD;
      ACCES study) and 2) 11-14 weeks after the beginning of saxagliptin or placebo (Chronic ACCES&#xD;
      study).&#xD;
&#xD;
      We will evaluate at fasting and each hour after a standardized breakfast:&#xD;
&#xD;
      (i) biological and metabolic parameters. Furthermore, an oral glucose tolerance test will be&#xD;
      performed at the end of the study.&#xD;
&#xD;
      (ii) by non-invasive devices arterial stiffness (Sphygmocor®), endothelial function (ENDOPAT&#xD;
      2000® ), cutaneous microcirculation (laser doppler Perimed ®.PF 5010) and cardiac autonomic&#xD;
      function(task force monitor®).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Vago-sympathetic activity.</measure>
    <time_frame>First day (inclusion) and after 11-14 weeks of treatment</time_frame>
    <description>This is a pilot study. The vascular measurements will be performed before and during a standardized breakfast.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>arterial stiffness</measure>
    <time_frame>First day (inclusion) and after 11-14 weeks of treatment</time_frame>
    <description>This is a pilot study. The vascular measurements will be performed before and during a standardized breakfast.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>endothelial function</measure>
    <time_frame>First day (inclusion) and after 11-14 weeks of treatment</time_frame>
    <description>This is a pilot study. The vascular measurements will be performed before and during a standardized breakfast.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>oral glucose tolerance test.</measure>
    <time_frame>First day (inclusion) and after 11-14 weeks of treatment</time_frame>
    <description>This is a pilot study. The vascular measurements will be performed before and during a standardized breakfast.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Impaired Glucose Tolerance</condition>
  <arm_group>
    <arm_group_label>Saxagliptin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Saxagliptin 5 mg (tablet) at BREAKFEAST</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>at BREAKFEAST</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>saxagliptin</intervention_name>
    <description>5mg a day for 11-14 weeks</description>
    <arm_group_label>Saxagliptin</arm_group_label>
    <other_name>Onglyza</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo pill</intervention_name>
    <description>one tablet a day for 11-14 weeks</description>
    <arm_group_label>placebo pill</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Social security affiliation&#xD;
&#xD;
          -  Persons without TUTORSHIP that can freely agree to participate to the study&#xD;
&#xD;
          -  Age between 18 to 70 years&#xD;
&#xD;
          -  Impaired glucose tolerance diagnosed during the previous month.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Breast feeding&#xD;
&#xD;
          -  Diabetes&#xD;
&#xD;
          -  No contraception&#xD;
&#xD;
          -  Body Mass Index &gt; 45 kg/m²&#xD;
&#xD;
          -  Arterial blood pressure &gt; 160/110 mmHg&#xD;
&#xD;
          -  Creatinine clearance &lt; 60 ml/min&#xD;
&#xD;
          -  Severe hepatocellular insufficiency&#xD;
&#xD;
          -  Chronic respiratory disease&#xD;
&#xD;
          -  Anaemia (Hemoglobin &lt; 10 g/dl)&#xD;
&#xD;
          -  Peripheral arterial occlusive disease&#xD;
&#xD;
          -  Heart failure&#xD;
&#xD;
          -  Cardiac arrhythmia&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Valensi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jean Verdier Hospital - Department of Endocrinology-Diabetology-Nutrition</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jean Verdier hospital, Department of Endocrinology-Diabetology-Nutrition</name>
      <address>
        <city>Bondy</city>
        <zip>93140</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <study_first_submitted>November 22, 2011</study_first_submitted>
  <study_first_submitted_qc>January 25, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 30, 2012</study_first_posted>
  <last_update_submitted>February 2, 2015</last_update_submitted>
  <last_update_submitted_qc>February 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Impaired glucose tolerance</keyword>
  <keyword>Saxagliptin</keyword>
  <keyword>Cardiovascular risk integrators</keyword>
  <keyword>Vago-sympathetic activity</keyword>
  <keyword>Arterial stiffness</keyword>
  <keyword>Endothelial function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucose Intolerance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Saxagliptin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

